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Abstract: Secondary (AA) amyloidosis is a multisystem disorder complicating chronic 
  infections or inflammatory diseases. It is characterized by extracellular deposit of fibrils 
  composed of fragments of serum amyloid A (SAA), an acute phase reactant protein. The kidney 
is the most frequent organ involved, manifesting as progressive proteinuria and renal impairment. 
Attenuation of the level of circulating SAA protein by treating the underlying inflammatory 
condition remains the primary strategy in treating AA amyloidosis. However, at times, achieving 
adequate control of protein production can prove difficult. In addition, relapse of renal function 
often occurs rapidly following any subsequent inflammatory stimulus in patients with existing 
amyloidosis. Recently there has been an interest in finding other potential strategies targeting 
amyloid deposits themselves. Eprodisate is a sulfonated molecule with a structure similar to 
heparan sulfate. It competitively binds to the glycosaminoglycan-binding sites on SAA and 
inhibits fibril polymerization and amyloid deposition. Recent randomized clinical trial showed 
that it may slow down progressive renal failure in patients with AA amyloidosis. However 
confirmatory studies are needed and results of a second Phase III study are eagerly awaited to 
clarify whether or not eprodisate has a place in treating renal amyloid disease.
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Introduction
The amyloidoses are a group of heterogeneous, life-threatening diseases, characterized 
by the deposition of highly organized, insoluble protein aggregates within organs and 
normal tissue. The abnormal deposition of β-sheet fibrillar proteins results in either 
localized or systemic disease and can be hereditary or acquired in nature. In the systemic 
form of the disease, it is possible for deposits to occur in all tissues of the human body 
with the exception of the brain (this is seen in locally occurring amyloid deposits in 
Alzheimer’s disease). The binding of Congo red stain to the β-pleated sheet emits a 
characteristic apple-green birefringence under polarized light, allowing a diagnosis 
of amyloidosis to be made.
To date, 28 structurally unrelated precursor proteins have been described that have 
the capacity to adopt a β-sheet structure.1 All of these proteins are naturally soluble, 
and through processes of cleavage, aggregation, and misfolding, form fibrils with an 
abnormal β-sheet morphology.2 The two most common precursor proteins implicated in 
the formation of amyloid proteins include monoclonal light chains leading to primary 
or AL amyloidosis, and serum amyloid A (SAA), which in turn causes secondary 
(reactive) or AA amyloidosis.
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AA amyloidosis mainly occurs as a result of chronic 
inflammatory states, such as rheumatoid arthritis, ankylos-
ing spondylitis, or psoriatic arthritis but can also result from 
chronic infections, Familial Mediterranean Fever (FMF), 
or Crohn’s disease (Table 1). Less commonly, Castleman’s 
disease, vasculitis, and cancers have also been implicated.3 
A recent single-center study detailing 20 years’ Florentine 
experience of AA amyloidosis showed that rheumatoid 
arthritis contributed to 45% of cases and 67% of patients had 
some form of renal involvement.4 Other recent studies have 
shown that 5%–17% of patients with rheumatoid arthritis 
have amyloidosis reported as the cause of death.5 In a study of 
374 patients with AA amyloidosis, Lachmann et al reported 
that patients can experience symptoms of inflammatory dis-
ease for a median duration of approximately 17 years before 
a diagnosis of amyloidosis is made.3
The kidney is the organ chiefly affected by AA amy-
loidosis, manifesting as progressive proteinuria, nephrotic 
syndrome, and renal dysfunction.3,6 Up to 40% of patients 
with AA amyloidosis develop end stage renal failure.3 The 
complications arising as a result of renal failure are the cause 
of death in 40%–60% of cases, with a median survival after 
diagnosis of 4–8 years.7–9 Old age, end stage renal failure at 
presentation, reduced serum albumin level, and persistent 
higher levels of SAA concentration are associated with 
poor prognosis.3
Hepatic amyloid deposits are present in nearly a quar-
ter of the patients affected with secondary amyloidosis.3 
  Gastrointestinal involvement, which manifests as diarrhea 
and malabsorption syndrome, is present in approximately 
20% of patients. The incidence of gastrointestinal dis-
ease is increasing as the availability of renal replacement 
therapy has led to the extension of patients’ lives and their 
  subsequent ability to accumulate increasing amounts of 
amyloid deposits.3,10
In contrast with primary (AL) amyloidosis, other clini-
cal features such as thyroid, splenic, cardiac, and autonomic 
nerve involvement are less frequent.11 The survival rates have 
been shown to improve upon treatment of the underlying 
inflammatory condition.12–14
Pathophysiology of AA amyloidosis
The precursor SAA is a 104-amino-acid protein that is 
produced in response to inflammatory stimuli but its exact 
function remains unclear. This is an acute phase reactant 
and is produced in the liver in response to pro-inflammatory 
cytokines, and can be up regulated by up to 1000 times during 
episodes of acute inflammation.15,16 The principal cytokines 
involved in SAA induction are tumor necrosis factor (TNF), 
interleukin 1 (IL-1), interleukin 6 (IL-6), transcription factors 
such as SAA activating factor (SAF-1), and lipopolysaccha-
ride (LPS).17–19 In addition, it has also been demonstrated that 
hepatic clearance of SAA during episodes of inflammation 
(both acute and chronic) is reduced, hence the elevated levels 
witnessed.20
SAA is found in the serum as an apolipoprotein.21 Under 
normal circumstances it is degraded without the development 
of amyloid fibrils.22 In patients with amyloidosis however, the 
intermediate SAA products combine to form fibrils. These 
fibrils are deposited in the extracellular space of tissues and 
organs. Glycosaminoglycans such as heparan or dermatan 
sulfate, and serum amyloid P (SAP) then bind to these 
fibrils, which are then rendered invulnerable to degradation 
(Figure 1).23–25 However, not all patients with chronic inflam-
mation develop this complication and it remains largely 
unclear why some patients are prone to develop secondary 
(AA) amyloidosis while the others are protected. Certain 
genetic factors have been shown to increase the propensity 
for developing amyloidosis, such as polymorphisms in the 
gene coding for SAA1. Patients who are homozygous for 
the SAA1 isotype have a three- to sevenfold increased risk 
of developing amyloidosis.26–28 Other factors such as matrix 
metalloproteinase proteins (MMP), isoprenoid metabolism, 
heat shock proteins, and cathepsin D have also been impli-
cated in the pathogenesis of AA amyloidosis.29
The exact mechanism by which the deposits affect organ 
function is not well known. Clearly large deposits can distort 
the integrity and function of a tissue on a structural level. 
Whilst positive correlations exist between the size of amyloid 
deposits and disease severity, there is a variable relationship 
Table 1 List of causes of AA amyloid in order of incidence
Rheumatoid arthritis
Juvenile idiopathic arthritis
Other chronic inflammatory arthritides
Bronchiectasis
Familial Mediterranean fever
Unknown cause
Crohn’s disease
Other source of chronic sepsis (osteomyelitis, tuberculosis, etc)
Injection-drug abuse
Complications of paraplegia
Castleman’s disease
TNF-receptor associated periodic fever syndrome
Neoplasia
Vasculitis
Muckle–Wells syndrome
Abbreviation: TNF, tumor necrosis factor.
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between changes in renal function due to changes in size of 
amyloid deposits.30
It has been suggested that amyloidogenic precursor pro-
teins and intermediate filaments have direct toxic effects on 
the tissues, which are independent of the amyloid deposits. 
These toxicities might directly contribute to the disease 
manifestations. This view is supported by observations that 
proteinuria decreases rapidly after chemotherapy for primary 
AL amyloidosis and treatment of the underlying inflammatory 
condition in secondary AA amyloidosis, leading to a marked 
reduction in the production of the precursor amyloidogenic 
proteins.31,32 However, in a small published series, there was 
a lack of improvement in the size of amyloid deposits on 
repeat kidney biopsy in patients with primary AL amyloido-
sis following treatment, despite significant improvement in 
proteinuria.33,34 The measured level of serum SAA protein has 
been shown to correlate with disease activity and is a useful 
prognostic marker, and the outcome is thought to be favorable 
if the plasma SAA concentration is kept below 10 mg/L.35
Current treatment options  
and challenges
Attenuation of the level of circulating SAA protein by way 
of treating the underlying inflammatory condition remains 
the primary strategy in treating AA amyloidosis. The median 
plasma concentration of SAA in healthy individuals is 
3 mg/L, but the concentration can be 650-fold higher during 
an acute-phase response.36 The relative risk of death amongst 
patients with a plasma SAA concentration of .155 mg/L is 
18 times greater than those with a plasma SAA concentration 
of ,4 mg/L, and four times greater than in patients with an 
SAA concentration of 4–9 mg/L.3 Lachmann et al reported 
an improvement in renal functions in patients with a median 
SAA concentration of 6 mg/L and deterioration in patients 
with a median SAA concentration of 28 mg/L.3 Proteinuria 
reduces significantly in patients with AA amyloidosis when 
the underlying inflammatory disease becomes quiescent.31
Chronic pyogenic and granulomatous diseases (par-
ticularly tuberculosis) previously accounted for a far higher 
proportion of cases and were successfully treated with 
antimicrobial therapy and surgery for those with abscesses 
and osteomyelitis. Other therapeutic interventions include 
colchicine, which has been successfully used to treat FMF, 
thus preventing or treating the associated secondary AA 
amyloidosis.3,37 Conditions previously associated with AA 
amyloidosis such as Hodgkin’s disease have virtually been 
eliminated as a cause with increasingly effective chemo-
therapeutic agents. The majority of cases now seen in the 
SAA
Infection/Inflammation
Increased expression of IL-1/IL-6/TNF-α
Upregulation of hepatic SAA production
uptake by macrophages
Amyloid enhancing factors
other cause?
C-terminal cleavage of SAA
Fibril deposition in extracellular space
Immune to proteolysis
Binding of GAGs, SAP, and lipid components
β-sheet configuration
SAA
SAA
SAA
Figure 1 The pathogenesis of amyloid fibrils. 
Abbreviations: SAA, serum amyloid A; IL-1, interleukin-1; IL-6, interleukin 6; TNF-α, tumour necrosis factor alpha; GAG, glycosaminoglycan; SAP, serum amyloid P.
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developed world reflect the increasingly efficient treatment of 
infectious diseases, and are seen in those with inflammatory 
arthritides. Regression of amyloid deposits in these patients is 
dependent upon successful treatment with immunosuppres-
sive strategies or biological agents such as anti-TNF therapies 
or interleukin-1 receptor antagonists.38,39 The increase in use 
of disease-modifying agents and biological treatments for 
rheumatic diseases has led to a subsequent decline in the 
incidence of patients requiring renal replacement therapy 
for amyloid.40
Targeting the production of amyloidogenic proteins is a 
potentially effective strategy, but achieving adequate con-
trol of protein production can prove difficult. In addition, 
relapse of renal function often occurs rapidly following any 
subsequent inflammatory stimulus in patients with existing 
amyloidosis. Murine studies have suggested that the presence 
of an amyloid-enhancing factor (AEF) fast-tracks further 
surges of SAA into amyloid formation.41 Other potential 
strategies that have been attempted include targeting of the 
amyloid deposits themselves. Serum amyloid P (SAP) is a 
plasma glycoprotein that is bound to the β-sheets and ubiq-
uitous in all amyloid tissues, regardless of the sub-type. The 
presence of SAP has formed the basis for a key assessment 
tool allowing quantification of amyloid deposition in tis-
sues, by the binding of radioisotope-labeled SAP to amyloid 
deposits.42 Therapies targeting SAP have previously been 
developed that target the SAP–amyloid fibril interaction and 
allow the removal of SAP by the liver.43 SAP monoclonal 
antibodies have also been developed in murine models and 
have been shown to reduce visceral amyloid deposits by 
triggering a complement-dependent macrophage-derived 
reaction.44 Recently, antisense oligonucleotides have also 
been successfully used to downregulate expression of SAA 
in animal models.45
Introduction to eprodisate
As mentioned above, sulfated glycosaminoglycans, such as 
dextran and heparan sulfate, are always associated anatomi-
cally with amyloid deposits, regardless of the nature of the 
protein deposited, and are necessary for the assembly of the 
fibrils as well as the stability of tissue amyloid deposits.46–49 
Heparan sulfate is considered to be responsible for the 
stability of SAA2, which is the immediate precursor to AA 
amyloid in adopting the β-sheet structure that is characteristic 
of the amyloid protein-folding patterns.50 Pre-clinical studies 
using small-molecule anionic sulfonates or sulfates signifi-
cantly reduced murine splenic AA amyloid progression by 
disruption of the heparan sulfate-β-peptide fibril aggregate 
by competitively binding to the glycosaminoglycan-binding 
sites, thus inhibiting fibril polymerization.51 Four compounds 
were shown to be significantly effective in a dose-dependent 
manner in animal models, and of these, 1–3 propanedisul-
fonic acid disodium salt or eprodisate (NC-503, Kiacta®, 
previously Fibrillex™, marketed by Neurochem, Laval, 
Canada), was taken forward to human studies and used in 
the Phase III eprodisate for AA amyloidosis (EFAAT) trial. 
Eprodisate is similar in structure to heparan sulfate and is a 
low molecular weight, negatively charged, sulfonated mol-
ecule (Figure 2).51,52
Pharmacokinetics safety  
and efficacy
Pre-clinical pharmacokinetic studies showed that eprodis-
ate has good bioavailability when administered orally and 
is not protein-bound.52 Pharmacokinetic analysis of Phase I 
studies involving healthy volunteers showed a high inter-
individual variability in plasma concentration following 
oral doses ranging from 100–2400 mg. Maximum plasma 
concentrations were reached within 15–60 minutes post-
dose. A plasma half-life of approximately 10–20 hours 
was estimated from a multiple rising oral dose study.49 
Eprodisate is primarily excreted by the kidneys and the 
plasma concentration is increased in patients with renal 
impairment requiring dose adjustment.49,52 Animal stud-
ies using eprodisate at a high daily dose of 2 gm/kg/day 
over a 10-month period showed that the drug was well 
tolerated with low toxicity potential and was found to be 
nonmutagenic.53
Eprodisate was assessed in a multicenter,   randomized, 
double-blind, placebo-controlled trial to evaluate its 
efficacy and safety in patients with AA amyloidosis and 
renal involvement.54 Renal involvement was defined as 
  proteinuria of greater than 1 g/day or a creatinine clear-
ance of ,60 mL/minute. Patients were excluded if their 
creatinine clearance was ,20 mL/minute or they had renal 
O
O
O−
O−
O
O
S S
Na+
Na+
Figure 2 The chemical structure of 1,3 propanedisulfonic acid disodium salt.
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disease attributable to other than AA amyloidosis.   Significant 
liver dysfunction and diabetes were also amongst the 
exclusion criteria.
One hundred and eighty-three patients were assigned to 
the treatment drug, or placebo, and were well matched for 
age, gender and weight. Drug dosages were calculated 
according to baseline renal function. The study drug was 
administered orally twice daily at least 1 hour before or 
2 hours after a meal. Patients with creatinine clearance rates 
of less than 30 mL per minute received a total of 800 mg of 
eprodisate per day in two divided doses, those with rates 
of 30–80 mL per minute received a total of 1600 mg per 
day in two divided doses, and those with rates of more than 
80 mL per minute received a total of 2400 mg of eprodisate 
per day in two divided doses. Doses were decreased during 
the study if creatinine clearance decreased. Treatment of 
the underlying inflammatory disease was determined by the 
patient’s physician. Patients were followed up 4 monthly for 
a total of 2 years.
The primary endpoint of the study was a composite of 
decline in renal function or death. Worsening renal function 
was defined as doubling of serum creatinine, 50% reduction 
in creatinine clearance from the baseline, or progression to 
end-stage renal failure. Of the 183 patients, 124 completed 
the study. The adverse events were similar between the two 
groups. There were five deaths in each group during or within 
15 days after completion of administration of the study drug. 
Two patients in the eprodisate group died of ischemic stroke, 
one patient had nephrotic syndrome as cause of death while 
one each had gastrointestinal hemorrhage and pneumonia. 
The deaths in the placebo group were due to ischemic stroke, 
amyloid cardiomyopathy, bowel perforation, sepsis, and 
pancytopenia in one patient each. None of the deaths were 
considered to be related to eprodisate itself.
There was a clear trend towards arresting the decline 
in renal function in the treatment group compared to the 
placebo group with a 42% reduction seen (0.37–0.93, 
P = 0.02), which was independent of baseline renal function 
or circulating SAA concentration. Urinary protein excretion, 
however, was not affected. Some discrepancies were evi-
dent; the placebo arm had significantly more patients with 
a higher diastolic blood pressure and had a higher median 
serum creatinine level. The placebo arm also tended towards 
higher median SAA and C-reactive protein (CRP) levels 
although the differences between the two arms were not 
statistically significant (P = 0.14 for both). The treatment 
arm had significantly more patients with chronic infections 
(21 versus 9, P = 0.01) raising the possibility that treatment 
with   antimicrobial therapy may have partially accounted for 
some of the effect seen, given that median SAA and CRP lev-
els were lower in this group. The acknowledged mechanism 
of action of eprodisate means that the glycosaminoglycan-
amyloid fibril complex is disrupted, thereby preventing 
formation of new amyloid deposits. This is possibly why 
renal function in the treatment arm declined more slowly 
than in the placebo arm. There appeared to be no improve-
ment in the levels of proteinuria in the treatment group sug-
gesting that glomerular damage previously incurred by the 
kidney was not affected by the putative lack of development 
of additional amyloid deposits.
The future
In 2006, Neurochem Inc, announced that a letter had been 
received from the US Food and Drug Administration request-
ing further efficacy and safety information that would need to 
be addressed through additional clinical trials before approval 
would be given for its use in AA amyloidosis. One-year 
follow-up data from the original randomized trial revealed 
that eprodisate continued to be safe, and that comparisons 
looking at progression to dialysis/ESRD, or the composite 
endpoint of renal decline and death favored those patients 
in the treatment arm.55 In 2008, it was announced that a 
second Phase III trial would be initiated as recommended 
by both European and US regulatory agencies. Recruitment 
commenced in November 2010 and the estimated date of 
completion of the study is May 2014. The primary outcome 
measures are a decrease in creatinine clearance of 40% from 
baseline, an increase in serum creatinine of 80%, or progres-
sion to end-stage renal disease.56
Conclusion
Clinicians currently have a limited repertoire of therapeutic 
options when confronted with a patient with AA amyloido-
sis, although treating the underlying inflammatory condition 
remains the primary strategy. The preliminary results from 
Dember et al’s study54 are certainly encouraging and the 
results from the second Phase III study will clarify whether 
or not eprodisate has a place in treating renal amyloid   disease. 
At this stage, it is not known whether using eprodisate as 
an adjunctive therapy earlier on in the course of disease 
may affect outcomes, perhaps when SAA levels start to rise 
consistently above 4 mg/L. Strategies such as eprodisate 
that are designed to disturb the formation of amyloid fibrils, 
and other molecular techniques that target the stability of 
amyloid fibrils offer a new way of treating a potentially 
devastating condition.
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